OncoMatch/Clinical Trials/NCT07661641
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
Is NCT07661641 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 for breast cancer.
Treatment: [177Lu]Lu-A9-0631 · [225Ac]Ac-A9-0642 — This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of \[177Lu\]Lu-A9-0631 and \[225Ac\]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Prostate Cancer
Colorectal Cancer
Biomarker criteria
Required: GRPR expression (testing required; no eligibility threshold specified)
Have GRPR-expressing disease as confirmed by PET / CT or SPECT imaging
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: external beam radiation therapy to more than 25% of the bone marrow
Prior external beam radiation therapy to more than 25% of the bone marrow
Lab requirements
Blood counts
Adequate organ function within 14 days of first administration of investigational therapeutic product
Kidney function
Adequate organ function within 14 days of first administration of investigational therapeutic product
Liver function
Adequate organ function within 14 days of first administration of investigational therapeutic product
Adequate organ function within 14 days of first administration of investigational therapeutic product
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07661641 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior external beam radiation therapy to more than 25% of the bone marrow disqualifies patients from enrollment.
Does this trial require GRPR?
Yes, GRPR expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages